Platform for diagnosis / prognosis by miRNAs
The Acute Renal Failure is one of the most serious problems for kidney diseases in the developed countries due of high mortality, about 50%. Development of acute renal failure is also one of the most common complications after cardiac surgery, with an incidence of 30,000/year in Spain and more than 1% of them in our Hospital.
Current diagnostic methods are based on biomarkers of final damage, and do not allow to detect it earlier, with enough time to act and prevent it.
The present invention comprises 10 miRNAs (miR-127, miR-126, miR-210, miR-26b, miR-29a, miR-454, miR-146a, miR-27a, mi-R93 and miR-10a protected by patents), as markers for diagnosis and / or prognosis of acute kidney injury, further comprising a kit for use in clinical practice.
Spanish Patent Publication number 2363661, PCT ES2010070579
Spanish Patent Publication number 2414290, PCT ES2012070858
Both families have been extended into national phases in EPO, Brazil, Canada, México, USA, China, Japan, Russia, and India.
Diagnosis by miRNAs is a technique poorly invasive and can be performed from blood or urine patient’s samples.
Other biomarkers in development
The research group, led by Dr. Laura García Bermejo, is currently working on identifying miRNAs biomarkers for prognosis / early diagnosis of other diseases, such as breast cancer, colon cancer, pancreatic cancer...
Diego Velasco, Innovation Head
Emma González, Innovation Manager, PhD
Phone numbers: +34 91336 9132 / 9133
- Comercializado, Transferible
- Health technology:
- Biotecnología y Diagnóstico Molecular (proteómica, genómica, etc...)